JP2007500156A - 炎症性プロセスの治療におけるキナゾリンチロシンキナーゼ阻害剤の使用 - Google Patents

炎症性プロセスの治療におけるキナゾリンチロシンキナーゼ阻害剤の使用 Download PDF

Info

Publication number
JP2007500156A
JP2007500156A JP2006521478A JP2006521478A JP2007500156A JP 2007500156 A JP2007500156 A JP 2007500156A JP 2006521478 A JP2006521478 A JP 2006521478A JP 2006521478 A JP2006521478 A JP 2006521478A JP 2007500156 A JP2007500156 A JP 2007500156A
Authority
JP
Japan
Prior art keywords
amino
quinazoline
methoxy
chloro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006521478A
Other languages
English (en)
Japanese (ja)
Inventor
ビルジット ユング
フーベルト ピューシュナー
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2007500156A publication Critical patent/JP2007500156A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
JP2006521478A 2003-07-28 2004-07-22 炎症性プロセスの治療におけるキナゾリンチロシンキナーゼ阻害剤の使用 Pending JP2007500156A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10334226A DE10334226A1 (de) 2003-07-28 2003-07-28 Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
PCT/EP2004/008185 WO2005011701A1 (de) 2003-07-28 2004-07-22 Verwendung von chinazolin tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse

Publications (1)

Publication Number Publication Date
JP2007500156A true JP2007500156A (ja) 2007-01-11

Family

ID=34071934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006521478A Pending JP2007500156A (ja) 2003-07-28 2004-07-22 炎症性プロセスの治療におけるキナゾリンチロシンキナーゼ阻害剤の使用

Country Status (5)

Country Link
EP (1) EP1651228A1 (de)
JP (1) JP2007500156A (de)
CA (1) CA2533752A1 (de)
DE (1) DE10334226A1 (de)
WO (1) WO2005011701A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006082129A1 (de) * 2005-02-04 2006-08-10 Boehringer Ingelheim International Gmbh Verwendung von tyrosinkinase-inhibitoren zur behandlung der chronischen rhinosinusitis
KR20070107151A (ko) * 2005-02-26 2007-11-06 아스트라제네카 아베 티로신 키나제 억제제로서의 퀴나졸린 유도체
WO2010054285A2 (en) 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
WO2017141271A1 (en) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical composition of afatinib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6656946B2 (en) * 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042059A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10063435A1 (de) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10214412A1 (de) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10231711A1 (de) * 2002-07-13 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EA200701302A1 (ru) * 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы

Also Published As

Publication number Publication date
CA2533752A1 (en) 2005-02-10
EP1651228A1 (de) 2006-05-03
DE10334226A1 (de) 2005-02-17
WO2005011701A1 (de) 2005-02-10

Similar Documents

Publication Publication Date Title
US20070004720A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US20090306072A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US5096916A (en) Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
US8431585B2 (en) Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
US20070099918A1 (en) Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
JP2005524664A (ja) β２−アゴニストの溶液を含有する加圧式定量用量吸入器
EA026946B1 (ru) Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы
JP2007517828A (ja) 気道の疾患を治療するための置換プテリジンの使用
CA2667543A1 (en) New pharmaceutical combinations for treatment of respiratory and gastrointestinal disorders
KR20080067643A (ko) 호흡기 장애의 치료를 위한 신규한 약제학적 병용제제
JP2009529539A (ja) 呼吸器障害を治療するための方法および組成物
US11117865B2 (en) Inhibitors of bromodomain-containing protein 4 (BRD4)
JP2007509875A (ja) 炎症プロセスの治療のためのチロシンキナーゼインヒビターの使用
JP2009523700A (ja) 慢性鼻副鼻腔炎の治療のためのチロシンキナーゼ抑制剤の使用
US20050059661A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
JP2011511801A (ja) 呼吸器系疾患を処置するための方法及び組成物
JP2007500156A (ja) 炎症性プロセスの治療におけるキナゾリンチロシンキナーゼ阻害剤の使用
EP1755595A1 (de) Verwendung von roflumilast zur prophylaxe oder behandlung von emphysem
WO2013137009A1 (ja) 慢性閉塞性肺疾患改善剤
DE102005005505A1 (de) Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung der chronischen Rhinosinusitis
JP2004511542A (ja) 煙の吸入の治療のためのｐ３８阻害剤の使用
JP2009511586A5 (ja) 気道分泌過多を処置するための組成物および方法
JP2004307351A (ja) 慢性閉塞性肺疾患治療薬